Skip to main content

Advertisement

SpringerLink
Log in

Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Evidence on non-steroidal anti-inflammatory drugs (NSAID) use and breast cancer risk shows a slightly protective effect of these drugs, but previous studies lack randomized clinical trial results and present high heterogeneity in exposure measurement. This systematic review and meta-analysis widens the knowledge about NSAID use and breast cancer risk, updating the information from the last meta-analysis, focusing on evidence on specific effects of COX-2 inhibitors and differential expression patterns of hormonal receptors. A PubMed-database search was conducted to include all entries published with the keywords “BREAST CANCER NSAID ANTI-INFLAMMATORY” until 10/24/2013 providing original results from cohort studies, case–control studies, or randomized clinical trials with at least one reported relative risk (RR) or odds ratio (OR) on the association between any NSAID use and incidence of invasive breast cancer. This resulted in 49 publications, from which the information was retrieved about type of study, exposure characteristics, breast cancer characteristics, and breast cancer-NSAID association. Meta-analyses were performed separately for case–control and cohort studies and for different hormone-receptor status. NSAID use reduced invasive breast cancer risk by about 20 %. A similar effect was found for aspirin, acetaminophen, COX-2 inhibitors and, to a lesser extent, ibuprofen. The effect of aspirin was similar in preventing hormone-receptor-positive breast cancer. This meta-analysis suggests a slightly protective effect of NSAIDs-especially aspirin and COX-2 inhibitors- against breast cancer, which seems to be restricted to ER/PR+tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Carter CA, Milholland RJ, Shea W, Ip MM (1983) Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 43(8):3559–3562

    CAS  PubMed  Google Scholar 

  2. Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460

    Article  CAS  PubMed  Google Scholar 

  3. Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190(4):445–450

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908–7916

    Article  CAS  PubMed  Google Scholar 

  5. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252–266

    Article  CAS  PubMed  Google Scholar 

  7. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) U.S. preventive services task force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 146(5):365–375

    Article  PubMed  Google Scholar 

  8. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) U.S. preventive services task force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 146(5):376–389

    Article  PubMed  Google Scholar 

  9. Harris RE, Alshafie GA, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 20(8):2101–2103

    Google Scholar 

  10. Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13(4):559–583

    CAS  PubMed  Google Scholar 

  11. Howe LR (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9(4):210

    Article  PubMed Central  PubMed  Google Scholar 

  12. Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109(2):189–198

    Article  CAS  PubMed  Google Scholar 

  13. Howe LR, Lippman SM (2008) Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100(20):1420–1423

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159

    Article  PubMed Central  PubMed  Google Scholar 

  15. Harris RE, Namboodiri K, Stellman SD, Wynder EL (1995) Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 24(2):119–120

    Article  CAS  PubMed  Google Scholar 

  16. Harris R, Namboodiri K, Farrar W (1995) Epidemiologic-study of nonsteroidal antiinflammatory drugs and breast-cancer. Oncol Rep 2(4):591–592

    CAS  PubMed  Google Scholar 

  17. Rosenberg L (1995) Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 24(2):107–109

    Article  CAS  PubMed  Google Scholar 

  18. Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7(2):203–205

    Article  CAS  PubMed  Google Scholar 

  19. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S (1998) Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomark Prev 7(10):869–873

    CAS  Google Scholar 

  20. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29(2):72–76

    Article  CAS  PubMed  Google Scholar 

  21. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320(7250):1642–1646

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Cotterchio M, Kreiger N, Sloan M, Steingart A (2001) Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomark Prev 10(11):1213–1217

    CAS  Google Scholar 

  23. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22(3):303–309

    Article  CAS  PubMed  Google Scholar 

  24. Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14(10):915–922

    Article  PubMed  Google Scholar 

  25. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291(20):2433–2440

    Article  CAS  PubMed  Google Scholar 

  26. Swede H, Mirand AL, Menezes RJ, Moysich KB (2005) Association of regular aspirin use and breast cancer risk. Oncology 68(1):40–47

    Article  CAS  PubMed  Google Scholar 

  27. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the case–control surveillance study revisited. Am J Epidemiol 162(2):165–170

    Article  PubMed  Google Scholar 

  28. Harris RE, Beebe-Donk J, Alshafie GA (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 30(6):27

    Article  Google Scholar 

  29. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM (2006) Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8(6):R71

    Article  PubMed Central  PubMed  Google Scholar 

  30. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A (2007) Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28(2):427–434

    Article  CAS  PubMed  Google Scholar 

  31. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS (2007) Long-term aspirin use and mortality in women. Arch Intern Med 167(6):562–572

    Article  PubMed  Google Scholar 

  32. Davis S, Mirick DK (2007) Medication use and the risk of breast cancer. Eur J Epidemiol 22(5):319–325

    Article  PubMed  Google Scholar 

  33. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166(6):709–716

    Article  PubMed  Google Scholar 

  34. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomark Prev 16(4):747–755

    Article  CAS  Google Scholar 

  35. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, Shields PG, Freudenheim JL (2010) Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York exposures and breast cancer (WEB) Study. Cancer Causes Control 21(9):1503–1512

    Article  PubMed Central  PubMed  Google Scholar 

  36. Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sørensen HT (2010) Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res 12(2):R15

    Article  PubMed Central  PubMed  Google Scholar 

  37. Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20(1):66–70

    Article  PubMed  Google Scholar 

  38. Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, Shields PG, Freudenheim JL (2011) Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York exposures and breast cancer (WEB) study. Breast Cancer Res Treat 126(1):157–165

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Goerlitz DS, Trevisan M, Shields PG, Freudenheim JL (2011) Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 22(7):965–975

    Article  PubMed Central  PubMed  Google Scholar 

  40. Vinogradova Y, Coupland C, Hippisley-Cox J (2011) Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 105(3):452–459

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y (2013) Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer 109(7):1921–1925

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Ou SM, Chen YT, Chao PW, Lee YJ, Liu CJ, Yeh CM, Chen TJ, Chen TW, Yang WC, Li SY (2013) Nonsteroidal anti-inflammatory drug use is associated with cancer risk reduction in chronic dialysis patients. Kidney Int 84(1):198–205

    Article  CAS  PubMed  Google Scholar 

  43. Friedman GD, Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65(4):723–733

    CAS  PubMed  Google Scholar 

  44. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299(6710):1247–1250

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327

    CAS  PubMed  Google Scholar 

  46. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146

    Article  CAS  PubMed  Google Scholar 

  47. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88(14):988–993

    Article  CAS  PubMed  Google Scholar 

  48. Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6(1):71–73

    CAS  PubMed  Google Scholar 

  49. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA (2000) Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83(1):112–120

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97(1):96–101

    Article  CAS  PubMed  Google Scholar 

  51. Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11(12):1586–1591

    CAS  Google Scholar 

  52. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88(5):684–688

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Women’s health initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women’s health initiative. Cancer Res 63(18):6096–6101

    CAS  PubMed  Google Scholar 

  54. Sørensen HT, Friis S, Nørgård B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88(11):1687–1692

    Article  PubMed Central  PubMed  Google Scholar 

  55. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177–3184

    PubMed  Google Scholar 

  56. García Rodríguez LA, González-Pérez A (2004) Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91(3):525–529

    Article  PubMed Central  PubMed  Google Scholar 

  57. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomark Prev 14(1):261–264

    CAS  Google Scholar 

  58. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97(11):805–812

    Article  CAS  PubMed  Google Scholar 

  59. Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106(7):1443–1452

    Article  CAS  PubMed  Google Scholar 

  60. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121(1):211–215

    Article  CAS  PubMed  Google Scholar 

  61. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166(10):1150–1158

    Article  PubMed  Google Scholar 

  62. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615

    Article  CAS  PubMed  Google Scholar 

  63. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99(11):881–889

    Article  CAS  PubMed  Google Scholar 

  64. Friis S, Thomassen L, Sørensen HT, Tjønneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17(2):88–96

    Article  PubMed  Google Scholar 

  65. Ready A, Velicer CM, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109(3):533–543

    Article  CAS  PubMed  Google Scholar 

  66. Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the national institutes of health-AARP diet and health study. Breast Cancer Res 10(2):R38

    Article  PubMed Central  PubMed  Google Scholar 

  67. Siemes C, Visser LE, Coebergh JW, Hofman A, Uitterlinden AG, Stricker BH (2008) Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 8(8):753–764

    Article  CAS  PubMed  Google Scholar 

  68. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ Health Study II. Arch Intern Med 169(2):115–121

    Article  PubMed Central  PubMed  Google Scholar 

  69. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126(1):149–155

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L (2011) Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 22(11):1553–1561

    Article  PubMed  Google Scholar 

  71. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 30(28):3468–3477

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the women’s health study: a randomized controlled trial. JAMA 294(1):47–55

    Article  CAS  PubMed  Google Scholar 

  73. Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98(5):989–991

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Bulun SE, Lin Z, Imir G et al (2005) Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57(3):359–383

    Article  CAS  PubMed  Google Scholar 

  75. Asaga S, Jinno H, Sakata M, Kitajima M (2007) Current perspective of chemoprevention in breast cancer. Nihon Rinsho 65(Suppl 3):627–632

    PubMed  Google Scholar 

  76. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5):518–527

    Article  CAS  PubMed  Google Scholar 

  77. Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17(7):871–888

    Article  PubMed  Google Scholar 

  78. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23(6):1403–1415

    Article  CAS  PubMed  Google Scholar 

  79. González-Pérez A, García Rodríguez LA, López-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28

    Article  PubMed Central  PubMed  Google Scholar 

  80. Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55–67

    Article  CAS  PubMed  Google Scholar 

  81. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  82. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131(2):581–587

    Article  CAS  PubMed  Google Scholar 

  83. Mangiapane S, Blettner M, Schlattmann P (2008) Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 17(2):115–124

    Article  PubMed  Google Scholar 

  84. Takkouche B, Regueira-Méndez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439–1447

    Article  CAS  PubMed  Google Scholar 

  85. Tolentino Silva M, Freire Galvao T, Ricardo Zimmerman I, Gomes Pereira M, Cruz Lopes L (2012) Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence. Curr Pharm Des 18(26):4047–4070

    Article  Google Scholar 

  86. Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 117(1):141–150

    Article  CAS  PubMed  Google Scholar 

  87. Brockwell SE, Gordon IR (2001) A comparison of statistical methods for metaanalysis. StatMed 20:825–840

    CAS  Google Scholar 

  88. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  89. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

    Article  PubMed  Google Scholar 

  90. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Brit Med J 315:629–634

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  91. Light RJ, Pillemer DB (1984) Summing up: The science of reviewing research. Harvard University Press, Cambridge, MA

    Google Scholar 

  92. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463

    Article  CAS  PubMed  Google Scholar 

  93. Jin ZC, Zhou XH, He J (2014) Statistical methods for dealing with publication bias in meta-analysis. Stat Med. doi:10.1002/sim.6342

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, Spain

    María de Pedro

  2. Department of Obstetrics and Gynecology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain

    Sara Baeza

  3. Department of Obstetrics and Gynecology, Marqués de Valdecilla University Hospital, Santander, Spain

    María-Teresa Escudero

  4. Department of Preventive Medicine, University of Cantabria Medical School – IDIVAL, and CIBER Epidemiologia y Salud Publica (CIBERESP), Santander, Spain

    Trinidad Dierssen-Sotos, Inés Gómez-Acebo & Javier Llorca

  5. Unit of Cancer Epidemiology, National Center of Epidemiology (Institute of Health Carlos III) and CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain

    Marina Pollán

  6. Facultad de Medicina (Medicina Preventiva), Avda. Herrera Oria s/n, 39011, Santander, Cantabria, Spain

    María de Pedro

Authors
  1. María de Pedro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara Baeza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María-Teresa Escudero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Trinidad Dierssen-Sotos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inés Gómez-Acebo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina Pollán
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Javier Llorca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María de Pedro.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Pedro, M., Baeza, S., Escudero, MT. et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Res Treat 149, 525–536 (2015). https://doi.org/10.1007/s10549-015-3267-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3267-9

Keywords

Search

Navigation